Summary
Goodwin Procter is a sponsor of Nature BioTech's SciCafe series, which focuses on critical themes in the life sciences world. June 2013’s meeting will include two neuroscience speakers and an industry panel that will discuss the translational challenges in neuro-developmental disorders research.
Related Content
- Big Molecule WatchFebruary 14, 2025
Dr. Reddy’s Secures License from Henlius to Market Daratumumab Biosimilar in the U.S. and Europe
- Big Molecule WatchFebruary 11, 2025
Regulatory and Commercial Updates on Bio-Thera’s BAT2506 (golimumab)
- Big Molecule WatchFebruary 10, 2025
HyClone Seeks to Quash Amgen’s Subpoena Issued in Denosumab BPCIA Litigation Against Fresenius
- Big Molecule WatchFebruary 7, 2025
EU Biosimilar Regulatory and Launch Updates
- Big Molecule WatchFebruary 6, 2025
BioNTech Acquires Biotheus To Boost Oncology Strategy
- Life Sciences PerspectivesFebruary 6, 2025
Medtech M&A and VC Signal Positive Momentum Entering 2025
- Big Molecule WatchFebruary 6, 2025
Federal Circuit Affirms Injunction Against Samsung and Formycon in Aflibercept BPCIA Litigation
- Big Molecule WatchFebruary 6, 2025
FDA Accepts BLA for Shanghai Henlius Biotech’s HLX11, a Pertuzumab Biosimilar
- Speaking EngagementsFebruary 28, 2025
Yale OCS STEM PhD Pathways: Navigating Career Paths in Patent Law with Miho Kaneko
- Awards and RankingsFebruary 14, 2025
Chambers Global 2025 Recognizes Goodwin Lawyers and Practices as Worldwide Leaders
- Press ReleaseFebruary 12, 2025
Goodwin Advises Sionna Therapeutics on the Closing of its $219.2 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Press ReleaseFebruary 11, 2025
Anthos Therapeutics To Be Acquired by Novartis For Up To $3.1 Billion
- Awards and RankingsFebruary 6, 2025
Goodwin Paris Recognized by Chambers France 2025
- EventFebruary 5, 2025
Goodwin Rare Disease Symposium 2025
- Press ReleaseFebruary 4, 2025
Goodwin Advises Akero Therapeutics on the Closing of its $402.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Press ReleaseFebruary 3, 2025
Goodwin Advised Aclarion on the $4.7 Million Closing of Registered Direct Offering of Common Stock